Gaynes Bradley N, Pence Brian W, Atashili Julius, O'Donnell Julie K, Njamnshi Alfred K, Tabenyang Mbu Eyongetah, Arrey Charles Kefie, Whetten Rachel, Whetten Kathryn, Ndumbe Peter
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.
Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, United States of America.
PLoS One. 2015 Oct 15;10(10):e0140001. doi: 10.1371/journal.pone.0140001. eCollection 2015.
Little is known about how improved depression care affects HIV-related outcomes in Africa. In a sample of depressed HIV patients in a low income, sub-Saharan country, we explored how implementing measurement-based antidepressant care (MBC) affected HIV outcomes over 4 months of antidepressant treatment.
As part of a project adapting MBC for use in Cameroon, we enrolled 41 depressed HIV patients on antiretroviral therapy in a pilot study in which a depression care manager (DCM) provided an outpatient HIV clinician with evidence-based decision support for antidepressant treatment. Acute depression management was provided for the first 12 weeks, with DCM contact every 2 weeks and HIV clinician appointments every 4 weeks. We measured HIV clinical and psychiatric outcomes at 4 months.
Participants were moderately depressed at baseline (mean Patient Health Questionnaire [PHQ] score = 14.4, range 13.1, 15.6). All HIV clinical outcomes improved by four month follow-up: mean (range) CD4 count improved from 436 (2, 860) to 452 (132, 876), mean (range) log-viral load decreased from 4.02 (3.86, 4.17) to 3.15 (2.81, 3.49), the proportion with virologic suppression improved from 0% to 18%, mean (range) HIV symptoms decreased from 6.4 (5.5, 7.3) to 3.1 (2.5, 3.7), the proportion reporting good or excellent health improved from 18% to 70%, and the proportion reporting any missed ARV doses in the past month decreased from 73% to 55%. Concurrently, psychiatric measures improved. The mean (range) PHQ score decreased from 14.4 (13.1, 15.6) to 1.6 (0.8, 2.4) and 90% achieved depression remission, while mean maladaptive coping style scores decreased and mean adaptive coping scores and self-efficacy scores improved.
In this pilot study of an evidence-based depression treatment intervention for HIV-infected patients in Cameroon, a number of HIV behavioral and non-behavioral health outcomes improved over 4 months of effective depression treatment. These data are consistent with the hypothesis that better depression care can lead to improved HIV outcomes.
关于改善抑郁症治疗如何影响非洲地区与艾滋病病毒(HIV)相关的结果,我们知之甚少。在撒哈拉以南一个低收入国家的抑郁症HIV患者样本中,我们探讨了实施基于测量的抗抑郁治疗(MBC)在4个月的抗抑郁治疗期间如何影响HIV相关结果。
作为将MBC应用于喀麦隆的一个项目的一部分,我们在一项试点研究中招募了41名接受抗逆转录病毒治疗的抑郁症HIV患者,其中一名抑郁症护理经理(DCM)为一名门诊HIV临床医生提供基于证据的抗抑郁治疗决策支持。在前12周提供急性抑郁症管理,DCM每2周联系一次,HIV临床医生每4周安排一次预约。我们在4个月时测量HIV临床和精神方面的结果。
参与者在基线时中度抑郁(患者健康问卷[PHQ]平均得分=14.4,范围13.1至15.6)。到4个月随访时,所有HIV临床结果均有所改善:CD4细胞计数平均值(范围)从436(2至860)提高到452(132至876),病毒载量对数平均值(范围)从4.02(3.86至4.17)降至3.15(2.81至3.49),病毒学抑制比例从0%提高到18%,HIV症状平均值(范围)从6.4(5.5至7.3)降至3.1(2.5至3.7),报告健康状况良好或极佳的比例从18%提高到70%,报告过去一个月有任何漏服抗逆转录病毒药物剂量的比例从73%降至55%。同时,精神方面的指标也有所改善。PHQ平均得分(范围)从14.4(13.1至15.6)降至1.6(0.8至2.4),90%的患者实现抑郁症缓解,同时适应不良应对方式平均得分降低,适应性应对平均得分和自我效能感得分提高。
在喀麦隆针对HIV感染患者的基于证据的抑郁症治疗干预的这项试点研究中,经过4个月有效的抑郁症治疗,多项HIV行为和非行为健康结果得到改善。这些数据与更好的抑郁症治疗可导致HIV相关结果改善的假设一致。